ArticleBJUI compass2026
Effect of extending the oral administration period of 5-aminolevulinic acid on diagnostic accuracy and treatment outcomes for non-muscle-invasive bladder cancer.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the treatment outcomes of 5-aminolevulinic acid hydrochloride (5-ALA) photodynamic diagnosis (PDD)-assisted transurethral resection of bladder tumour (TURBT) (ALA PDD-TURBT, hereinafter referred to as 'ALA-PDD') exceeding 4 h after ALA administration for non-muscle-invasive bladder cancer (NMIBC). Patients and methods: This retrospective single-centre study included 386 patients who had undergone TURBT with or without 5-ALA for NMIBC between January 2018 and December 2024. Patients who received 5-ALA were divided into two groups based on 5-ALA exposure times before TURBT: 2-4 h and 4-8 h groups. The diagnostic sensitivity and specificity of procedures performed after the two exposure times were calculated by comparing cystoscopy findings with pathological findings in the ALA-PDD group. Recurrence-free survival (RFS) and progression-free survival (PFS) rates of NMIBC patients in the white-light (WL) and ALA-PDD groups were examined using Kaplan-Meier curves. Results: When the same lesion was evaluated using WL and fluorescent light (FL) modes, the sensitivity was 62.6% for the former and 93.2% for the latter. Furthermore, when the FL mode was divided into two ALA-PDD groups, the sensitivity was 93.9% in the 2-4 h group and 91.3% in the 4-8 h group ( Conclusion: The clinical efficacy of ALA-PDD, in terms of sensitivity and recurrence, was maintained even when the 5-ALA administration time was extended from 2 to 4 h to 2-8 h prior to TURBT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.